More and more wealthy Chinese patients travel overseas for healthcare. It costs a lot, and they pay it anyway. The reason is simple: for certain conditions and certain check-ups, they trust foreign medicine more than what they can get at home. This has been building for a decade, and in 2026 the profile of the traveler has changed. It is no longer the mass patient looking for a cheaper operation. It is the high-net-worth individual (HNWI) looking for the best cancer specialist, the most complete check-up, or a treatment that is simply not legal or available in China. In this article I will break down why they leave, where they go, and how a foreign clinic or hospital actually reaches this client. This is close work I do with healthcare providers entering China, so I will keep it concrete.
Written by Olivier Verot, founder of GMA. I have run China market-entry campaigns for hospitals, IVF clinics, and medical facilitators since 2012, from Shanghai. I have seen what convinces a Chinese HNWI family to fly to Tokyo or Boston, and what makes them ignore a foreign clinic completely.
- Hundreds of thousands of Chinese travel abroad for care every year, in a market long estimated at around 10 billion USD in treatment and travel spend.
- Healthcare is one of the first concerns of the wealthy Chinese class.
- The buyer in 2026 is the HNWI patient and their family, not the price-shopper.
Why Wealthy Chinese Patients Still Leave in 2026
Wealth, age, and lifestyle diseases drive this. China has tens of millions more urban residents aged 40 to 65 than it did a few years ago, plus a fast-growing 65-plus group. These people have money, they have chronic conditions, and they no longer accept the first diagnosis they are given. When the stakes are high, they get on a plane.
What has changed is that the motives are now very specific. It is not “go abroad for better hospitals” in general. Each destination answers a precise need. Here is how it breaks down.
| Need | Where they go | Why |
|---|---|---|
| Premium check-up and prevention | Japan | Full-body cancer screening (PET, early detection), precision and discretion |
| Oncology and second opinion | United States, Germany, UK | Access to specialists, clinical trials, and drugs not yet approved in China |
| Assisted reproduction (IVF, egg freezing) | United States, Thailand, and other legal markets | Rules on eligibility and third-party options are stricter at home |
| Anti-aging and longevity | Switzerland | Established cell and longevity clinics, privacy for high-profile clients |
| Dental and aesthetics | South Korea, Thailand | Reputation, speed, and price for cosmetic and dental work |
The geography is lopsided. East Asia takes the large majority of Chinese outbound medical trips, around 85% by most industry counts, with Japan a leading destination. The United States and Europe, mainly Switzerland, the UK, and Germany, take a much smaller slice, a few thousand patients each per year. That small slice matters, because it is almost entirely HNWI and it spends the most per case. According to market analysts tracking outbound Chinese medical travel, this segment has anchored the roughly 10 billion USD value of the market for years.
Aesthetics deserves its own line. Chinese demand for cosmetic and anti-aging work abroad is large and growing. Reports in 2024 and 2025 put roughly a third of mid-to-high income aesthetic consumers as open to going abroad for procedures, with South Korea the top choice. Korea’s medical aesthetics market was worth about 572 million USD in 2023 and is projected to roughly double by 2029, a growth curve fed in good part by Chinese patients crossing the border for “medical aesthetics special forces” weekend trips. The China medical tourism market outlook confirms the same direction of travel for the higher-value segments.
One caveat for anyone reading the headlines. The flow is starting to run both ways. Chinese news reports describe foreign patient numbers into China rising sharply in 2025, and there is real talk about “medical plus tourism” becoming a top inbound format in 2026. That does not close the outbound door. It means the wealthy Chinese patient now compares a Shanghai international department against Tokyo and Boston, and you have to give them a reason to still choose you.
Who the HNWI Patient Actually Is
Picture the family, not the individual. The patient is often 45 to 70. The decision-maker is frequently the adult child, 28 to 40, who speaks some English, researches everything on their phone, and pays or co-pays. The source cities are predictable: Beijing, Shanghai, Shenzhen first, then Hangzhou, Guangzhou, Tianjin, Chengdu. These are people who already travel abroad, already hold assets outside China, and already expect a concierge level of service.
They are also anxious. Chinese patients have lived through fake hospitals, fake doctors, and fake medicine. They do not trust what a company says about itself. They trust what other Chinese patients say about you. That single fact should shape your entire China plan.
How a Foreign Health Facility Actually Reaches Them
Here is where most foreign clinics get it wrong. They build an English website, wait, and wonder why nothing happens. Reaching the Chinese HNWI patient is a specific stack of channels, and it starts and ends with trust.
A Chinese-language presence, built for Chinese search
Your website is still the official channel where an inquiry becomes real. It has to be in Mandarin. Two reasons. Technical: it is far easier to rank Mandarin pages on Baidu. Marketing: most searches on Baidu are in Chinese, and netizens expect any serious business to have a Chinese site. A clean, credible Chinese site is what turns a warm lead into a message. In 2026 add one layer the old playbook ignored: generative engine optimization. Chinese users now ask health questions to AI assistants like DeepSeek and Doubao, and increasingly search Xiaohongshu before they search Baidu. Your Chinese content needs to be structured so these engines quote you, not only so Baidu ranks you.
E-reputation is the backbone
What makes a scared patient contact you in the first place is recommendation. They have built a dense network of forums, Q&A boards, and now Xiaohongshu notes where they share experiences and ask which destination suits which disease. Being present and helpful in those conversations is the smartest early move you can make. If you wait for a natural reputation to form in a market this big, you will wait years. Balance this quiet, honest presence with official communication: online press releases on Chinese PR platforms. You can read more on how public relations works in China before you spend a yuan on it.
WeChat private domain, the real conversion engine
This is the piece the old article skipped, and in 2026 it is where deals close. A medical decision is slow, private, and full of questions. Paid ads cannot carry that. What works is private domain: you get the prospect into your WeChat, through an official account and a real person on a corporate WeChat, and you nurture them one to one. The mechanism matters. A medical advisor answers questions in Chinese, sends case explanations, arranges a video consult with the doctor, and stays in the chat for weeks or months until the family is ready. No lead is lost to an algorithm, because you own the relationship. For a slow, high-value, high-anxiety purchase, private domain is not a nice-to-have. It is the conversion engine.
Specialized intermediaries, private salons, and Xiaohongshu
Three more channels reach the HNWI patient directly. First, specialized medical facilitator agencies in China already hold the trust of these families and route them abroad; a partnership can bring qualified cases from day one, though you must vet the agency hard. Second, private salons and closed events, often through private banks, family offices, and luxury networks, put you in front of the exact profile you want in a discreet room. Third, Xiaohongshu content: honest, specific notes about your check-up experience, your oncology team, or your Swiss longevity program reach the researching adult child where they actually look. Show the place, the doctors, the process. Do not oversell.
A Case From My Desk: Isolde’s German Clinic
Isolde runs marketing for a private oncology and check-up clinic in Germany. She came to us after a year of trying. Her clinic had an English site, a machine-translated Chinese page, and a booth at one medical tourism fair. In twelve months they had generated eleven serious Chinese inquiries and closed two. The cost per closed case was embarrassing, and her board was ready to pull the China budget.
The paid-ad route had failed because a cancer second opinion is not an impulse click. People read, worried, and vanished. We rebuilt the base. A proper Mandarin site focused on second opinions and precision oncology, structured so Baidu and AI assistants could quote it. A Xiaohongshu account with real, careful notes from the clinic, no promises of cure. Most important, a WeChat private domain flow: every inquiry went to a Chinese-speaking medical advisor who answered questions for as long as the family needed and set up video calls with the German doctors.
The change was not magic and it was not instant. It took about seven months to build momentum. By month nine, qualified WeChat conversations were running four to five times the old inquiry volume, and the clinic had closed nine international cases, most from tier-one cities, at a far lower cost per case than the fair-and-ads approach. What worked was not a clever ad. It was trust, in Chinese, held in a private channel long enough for a frightened family to decide.
A Word on Sensitivity
This is health, so handle it with care. Health data is personal and regulated. Keep patient information off open channels, store it properly, and never publish a real case without clear consent. Topics like assisted reproduction touch legal and ethical lines that differ by country, so state facts about your service and local rules, and never imply you can bypass a law. And the hard rule for all medical marketing in China: no promises of outcome, no “guaranteed cure,” no before-and-after that reads as a medical claim. Chinese authorities restrict paid health ads for good reason, after past scandals. Credibility, not hype, is what sells here.
FAQ
Do we need a Chinese website if we already work with facilitator agencies?
Yes. Agencies bring cases, but the family will still search your name, and if they find nothing credible in Chinese they hesitate. A Mandarin site is your proof of existence and your official channel for inquiries. It also protects you: if an agency relationship ends, you keep your own presence and pipeline. Think of the agency as a source of leads and your Chinese site plus WeChat as the place you own the relationship.
How long before we see real inquiries from China?
Plan for six to nine months to build momentum, not six weeks. Trust in medical decisions is slow, and Baidu SEO plus e-reputation take time to compound. What you can accelerate is the private domain: once a lead enters WeChat, a good Chinese-speaking advisor shortens the path a lot. The clinics that quit at month three are the ones that waste money. The ones that commit to a year see a real, lower-cost pipeline.
Can we run paid ads to promote our treatments on Baidu?
Be careful. Baidu restricts paid advertising on many healthcare and treatment keywords, a legacy of past scandals with fake providers. You often cannot simply buy your way to the top for medical terms. That is why the durable strategy is SEO with a smart mix of low, medium, and high-competition keywords, strong e-reputation, and private domain conversion rather than a pure ad spend. It is slower, and it is the approach that actually holds up.
About GMA
GMA is a digital marketing agency based in Shanghai, focused on the Chinese market. We help foreign hospitals, clinics, IVF centers, and medical facilitators reach wealthy Chinese patients through Baidu SEO, Xiaohongshu, e-reputation, and WeChat private domain. We build the trust, in Chinese, that turns an anxious family into a booked case.
If you think China is a market for your facility, get in touch with our team. You can also see how the hospital market in China is developing and where the demand sits.
